☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
germline
AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastat...
December 30, 2019
Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Bre...
June 24, 2019
AstraZeneca and Merck's Lynparza (olaparib) Receive EU's Approval as a Monotherapy to Treat Germline BRCA-Mutated HER2-Negative Ad...
April 10, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.